SynthesisPloS one2015
Association between resistin levels and all-cause and cardiovascular mortality: a new study and a systematic review and meta-analysis.
Synthesis in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 3 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- Blood Circulating Levels of Adipokines in Polycystic Ovary Syndrome Patients: A Systematic Review and Meta-analysis.Reproductive sciences (Thousand Oaks, Calif.) · 2021Pooled it
- Age-specific ALS incidence: a dose-response meta-analysis.European journal of epidemiology · 2018Pooled it
- The PPARγ2 P12A polymorphism is not associated with all-cause mortality in patients with type 2 diabetes mellitus.Endocrine · 2016Pooled it
- Surgery for Obesity and Weight-Related Diseases Changes the Inflammatory Profile in Women with Severe Obesity: a Randomized Controlled Clinical Trial.Obesity surgery · 2021Trial
- Blood-based obesity biomarkers and their relevance for disease risk.Nature reviews. Endocrinology · 2026Review
- Review
- Biomarkers for Screening and Diagnosis of Heart Failure in Cardiovascular-Kidney-Metabolic Syndrome: A Narrative Review.International journal of molecular sciences · 2026Review
- DRIM modulates Src activation and regulates angiogenic functions in vascular endothelial cells.Cell biology international · 2025Article
- Circulating resistin levels and mutation burden of the RETN gene variants predict long-term mortality in a Taiwanese population.Scientific reports · 2025Article
- Resistin in cardiac diseases: from molecular mechanisms to clinical implications.Frontiers in endocrinology · 2025Review
- Development and Validation of a Predictive Score for Three-Year Mortality in Acute Ischemic Stroke Patients.Medicina (Kaunas, Lithuania) · 2024Article
- Omentin: A Key Player in Glucose Homeostasis, Atheroprotection, and Anti-Inflammatory Potential for Cardiovascular Health in Obesity and Diabetes.Biomedicines · 2024Review
- Interaction between Selected Adipokines and Musculoskeletal and Cardiovascular Systems: A Review of Current Knowledge.International journal of molecular sciences · 2023Review
- Adipokines and Bacterial Metabolites: A Pivotal Molecular Bridge Linking Obesity and Gut Microbiota Dysbiosis to Target.Biomolecules · 2023Review
- Upregulation of peripheral blood mononuclear cells resistin gene expression in severe obstructive sleep apnea and obstructive sleep apnea with coexisting type 2 diabetes mellitus.Sleep & breathing = Schlaf & Atmung · 2023Article
- Resistin as a risk factor for all-cause (and cardiovascular) death in the general population.Scientific reports · 2022Article
- Article
- Resistin deletion protects against heart failure injury by targeting DNA damage response.Cardiovascular research · 2022Article
- Differential prognostic value of resistin for cardiac death in patients with coronary artery disease according to the presence of metabolic syndrome.Heart and vessels · 2022Article
- Resistin and Cardiovascular Disease: A Review of the Current Literature Regarding Clinical and Pathological Relationships.Current cardiology reviews · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextStudies concerning the association between circulating resistin and mortality risk have reported, so far, conflicting results.
objectiveTo investigate the association between resistin and both all-cause and cardiovascular (CV) mortality risk by 1) analyzing data from the Gargano Heart Study (GHS) prospective design (n=359 patients; 81 and 58 all-cause and CV deaths, respectively); 2) performing meta-analyses of all published studies addressing the above mentioned associations. DATA SOURCE AND STUDY SELECTION: MEDLINE and Web of Science search of studies reporting hazard ratios (HR) of circulating resistin for all-cause or CV mortality. DATA EXTRACTION: Performed independently by two investigators, using a standardized data extraction sheet. DATA SYNTHESIS: In GHS, adjusted HRs per one standard deviation (SD) increment in resistin concentration were 1.28 (95% CI: 1.07-1.54) and 1.32 (95% CI: 1.06-1.64) for all-cause and CV mortality, respectively. The meta-analyses included 7 studies (n=4016; 961 events) for all-cause mortality and 6 studies (n=4,187: 412 events) for CV mortality. Pooled HRs per one SD increment in resistin levels were 1.21 (95% CI: 1.03-1.42, Q-test p for heterogeneity<0.001) and 1.05 (95% CI: 1.01-1.10, Q-test p for heterogeneity=0.199) for all-cause and CV mortality, respectively. At meta-regression analyses, study mean age explained 9.9% of all-cause mortality studies heterogeneity. After adjusting for age, HR for all-cause mortality was 1.24 (95% CI: 1.06-1.45).
conclusionsOur results provide evidence for an association between circulating resistin and mortality risk among high-risk patients as are those with diabetes and coronary artery disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.